Public health impact and cost-effectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programs
In China, progress to include the RV vaccine in the national immunization program (NIP) is slow. The only two vaccines, the Lanzhou lamb rotavirus vaccine (LLR) and Rotateq, are provided through the private market. This study aims to assess the health impact and cost-effectiveness of using three vac...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2090162 |
| _version_ | 1827806387319603200 |
|---|---|
| author | Jiahao Wang Haijun Zhang Haonan Zhang Hai Fang |
| author_facet | Jiahao Wang Haijun Zhang Haonan Zhang Hai Fang |
| author_sort | Jiahao Wang |
| collection | DOAJ |
| description | In China, progress to include the RV vaccine in the national immunization program (NIP) is slow. The only two vaccines, the Lanzhou lamb rotavirus vaccine (LLR) and Rotateq, are provided through the private market. This study aims to assess the health impact and cost-effectiveness of using three vaccines in the NIP, Rotateq, Rotarix, and LLR, compared to the status quo. A decision-tree Markov model was adopted to follow the 2019 birth cohort, and a societal perspective was used. Input parameters were based on the latest local data when possible. Outcomes included cases and deaths averted, quality-adjusted life years (QALYs) gained, and incremental cost-effectiveness ratios (ICER). Sensitivity analyses and scenario analyses to consider herd immunity and vaccine price reduction were performed. Including Rotateq in the NIP was projected to prevent 348 million RVGE cases (62.6% reduction) and 4251 deaths (72.6% reduction) compared to the status quo. Rotarix through the NIP would prevent 48.7% of cases and 63.2% of deaths, and LLR would avert 20.3% of cases and 22.4% of deaths. The ICERs per QALY gained were US$ 8833 for Rotateq through the NIP, US$ 9503 for Rotarix, and US$ 26,759 for LLR. In uncertainty analyses, the reduction of vaccine prices and the incorporation of herd immunity further improved the cost-effectiveness of the NIPs, especially Rotateq or Rotarix. In conclusion, introducing the RV vaccine in China’s NIP is expected to be cost-effective compared to the GDP per capita. Reducing vaccine prices and adopting vaccines with better efficacy would be the future focus. |
| first_indexed | 2024-03-11T21:40:27Z |
| format | Article |
| id | doaj.art-2b58159b1fca481cb19fe84335bedffa |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:40:27Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-2b58159b1fca481cb19fe84335bedffa2023-09-26T13:19:07ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-12-0118710.1080/21645515.2022.20901622090162Public health impact and cost-effectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programsJiahao Wang0Haijun Zhang1Haonan Zhang2Hai Fang3Peking UniversityPeking UniversityPeking UniversityPeking UniversityIn China, progress to include the RV vaccine in the national immunization program (NIP) is slow. The only two vaccines, the Lanzhou lamb rotavirus vaccine (LLR) and Rotateq, are provided through the private market. This study aims to assess the health impact and cost-effectiveness of using three vaccines in the NIP, Rotateq, Rotarix, and LLR, compared to the status quo. A decision-tree Markov model was adopted to follow the 2019 birth cohort, and a societal perspective was used. Input parameters were based on the latest local data when possible. Outcomes included cases and deaths averted, quality-adjusted life years (QALYs) gained, and incremental cost-effectiveness ratios (ICER). Sensitivity analyses and scenario analyses to consider herd immunity and vaccine price reduction were performed. Including Rotateq in the NIP was projected to prevent 348 million RVGE cases (62.6% reduction) and 4251 deaths (72.6% reduction) compared to the status quo. Rotarix through the NIP would prevent 48.7% of cases and 63.2% of deaths, and LLR would avert 20.3% of cases and 22.4% of deaths. The ICERs per QALY gained were US$ 8833 for Rotateq through the NIP, US$ 9503 for Rotarix, and US$ 26,759 for LLR. In uncertainty analyses, the reduction of vaccine prices and the incorporation of herd immunity further improved the cost-effectiveness of the NIPs, especially Rotateq or Rotarix. In conclusion, introducing the RV vaccine in China’s NIP is expected to be cost-effective compared to the GDP per capita. Reducing vaccine prices and adopting vaccines with better efficacy would be the future focus.http://dx.doi.org/10.1080/21645515.2022.2090162diarrhearotavirus vaccineeconomic evaluationcost-effectivenessvaccinationchina |
| spellingShingle | Jiahao Wang Haijun Zhang Haonan Zhang Hai Fang Public health impact and cost-effectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programs Human Vaccines & Immunotherapeutics diarrhea rotavirus vaccine economic evaluation cost-effectiveness vaccination china |
| title | Public health impact and cost-effectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programs |
| title_full | Public health impact and cost-effectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programs |
| title_fullStr | Public health impact and cost-effectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programs |
| title_full_unstemmed | Public health impact and cost-effectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programs |
| title_short | Public health impact and cost-effectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programs |
| title_sort | public health impact and cost effectiveness of rotavirus vaccination in china comparison between private market provision and national immunization programs |
| topic | diarrhea rotavirus vaccine economic evaluation cost-effectiveness vaccination china |
| url | http://dx.doi.org/10.1080/21645515.2022.2090162 |
| work_keys_str_mv | AT jiahaowang publichealthimpactandcosteffectivenessofrotavirusvaccinationinchinacomparisonbetweenprivatemarketprovisionandnationalimmunizationprograms AT haijunzhang publichealthimpactandcosteffectivenessofrotavirusvaccinationinchinacomparisonbetweenprivatemarketprovisionandnationalimmunizationprograms AT haonanzhang publichealthimpactandcosteffectivenessofrotavirusvaccinationinchinacomparisonbetweenprivatemarketprovisionandnationalimmunizationprograms AT haifang publichealthimpactandcosteffectivenessofrotavirusvaccinationinchinacomparisonbetweenprivatemarketprovisionandnationalimmunizationprograms |